# US 2019/0167839 A1 · Absorbable in situ gel-forming system, method of making and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167839 A1
- Document ID: US20190167839A1
- Status: Published application
- Kind: A1
- Application number: 16/253,276
- Filed: 2019-01-22
- Published: 2019-06-06
- Earliest claimed: 2011-10-17
- Applicants: Poly-Med, Inc.
- Inventors: Shalaby W. Shalaby; Jason Olbrich; Joel T. Corbett
- Web page: https://patentgrep.com/patent/US20190167839A1

## CPC

- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/65: Tetracyclines
- A61K 31/722: Chitin, chitosan
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/19: Platelets; Megacaryocytes
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/363: {Fibrinogen}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/4833: {Thrombin (3.4.21.5)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/0042: {Materials resorbable by the body}
- A61L 24/043: {Mixtures of macromolecular materials}
- A61L 31/041: {Mixtures of macromolecular compounds}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/145: {Hydrogels or hydrocolloids}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 35/00: Antineoplastic agents
- A61L 2400/04: Materials for stopping bleeding
- A61L 2400/06: Flowable or injectable implant compositions
- C12Y 304/21005: Thrombin (3.4.21.5)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed.

## Claims

### Claim at position 1

1-32. (canceled)

### Claim 33

An in situ gel-forming composition, comprising: one or more absorbable polymers; and
a solvent selected from the group consisting of N-methyl-2-pyrrolidone (NMP), polyethylene glycol (PEG), dimethyl sulfoxide (DMSO) and mixtures thereof, wherein said composition is an injectable liquid at a temperature in the range of about 18° C. to about 37° C. and forms a hydrogel or semi-solid mass on contact with an aqueous environment; wherein
the one or more absorbable polymers comprise a molecular chain having a X-Y-X or (X-Y)n structure, wherein X represents a relatively hydrophobic polyester block and Y represents a relatively hydrophilic block; and wherein
the X-Y-X or (X-Y)n structure is formed by grafting hydrophobic X blocks from monomers selected from the group consisting of glycolide, lactide, ε-caprolactone, p-dioxanone, trimethylene carbonate or combinations thereof, to hydrophilic Y blocks selected from the group consisting of polyoxyethylene, poly(oxyethylene-b-oxypropylene), polypeptide polyalkylene oxamate, polysaccharide, derivatives thereof, and liquid, high molecular weight polyether glycols interlinked with an oxalate or succinate functionalities in linear or branched form.

### Claim 34 (depends on 33)

The in situ gel-forming composition of claim 33, further comprising one or more bioactive agent.

### Claim 35 (depends on 34)

The in situ gel-forming composition of claim 34, wherein said one or more bioactive agents comprise a sclerosant.

### Claim 36 (depends on 33)

The in situ gel-forming composition of claim 33, wherein said one or more absorbable polymers comprise a segmented aliphatic polyurethane.

### Claim 37 (depends on 36)

The in situ gel-forming composition of claim 36, wherein said segmented aliphatic polyurethane is a lactide/glycolide based polyurethane.

### Claim 38 (depends on 37)

The in situ gel-forming composition of claim 37, wherein said lactide/glycolide based polyurethane has a lactide:glycolide mole ratio of 70:30 to 85:15.

### Claim 39 (depends on 36)

The in situ gel-forming composition of claim 36, wherein said segmented aliphatic polyurethane comprises polyoxyalkylene glycol chains covalently linked to polyester or polyester-carbonate chain segments, interlinked with aliphatic urethane segments.

### Claim 40 (depends on 39)

The in situ gel-forming composition of claim 39, wherein said polyoxyalkylene glycol chain has an average molecular weight of 200-1200 Dalton.

### Claim 41 (depends on 39)

The in situ gel-forming composition of claim 39, wherein said polyester or polyester-carbonate chain segments are derived from at least one cyclic monomer selected from the group represented by ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, l-lactide, dl-lactide, glycolide, morpholinedione, and combinations thereof

### Claim 42 (depends on 39)

The in situ gel-forming composition of claim 39, wherein said aliphatic urethane segments are derived from at least one diisocyanate selected from the group consisting of hexamethylene diisocyanate, lysine-derived diisocyanate, and cyclohexane bis (methylene isocyanate) at a prepolymer:diisocyanate ratio (w/w) of 1:0.6 to 1:1.4.

### Claim 43 (depends on 36)

The in situ gel-forming composition of claim 36, wherein said one or more absorbable polymers comprise a mixture of a copolymer of caprolactone/glycolide and a copolymer of lactide/glycolide.

### Claim 44 (depends on 36)

The in situ gel-forming composition of claim 36, wherein said one or more absorbable polymers comprise a mixture of a copolymer of lactide/trimethylene carbonate and a copolymer of lactide/glycolide.

### Claim 45 (depends on 36)

The in situ gel-forming composition of claim 36, wherein said one or more absorbable polymers comprise a terpolymer of lactide/carprolactone/trimethylene carbonate/glycolide.

### Claim 46 (depends on 33)

The in situ gel-forming composition of claim 33, wherein said one or more absorbable polymers comprise a molecular chain having a X-Y-X structure.

### Claim 47 (depends on 46)

The in situ gel-forming composition of claim 46, wherein said one or more absorbable polymers comprise a segmented aliphatic polyurethane.

### Claim 48 (depends on 33)

The in situ gel-forming composition of claim 33, wherein said one or more absorbable polymers comprise a molecular chain having a (X-Y)n structure

### Claim 49 (depends on 48)

The in situ gel-forming composition of claim 48, wherein said one or more absorbable polymers comprise a segmented aliphatic polyurethane.

### Claim 50 (depends on 33)

Use of an in situ gel-forming composition of claim 33 for treating a vascular disease or condition in a subject.

### Claim 51 (depends on 33)

Use of an in situ gel-forming composition of claim 33 for treating a cancer or tumor in a subject.

### Claim 52 (depends on 33)

Use of an in situ gel-forming composition of claim 33 for minimizing restenosis following angioplasty.
